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We live in exciting times. The last decade has seen a shift in
emphasis in medical practice toward an appropriate focus on opti-
mizing patient functional status and quality of life. In the field of
oncology, this trend has been associated with dramatic improve-
ments in anti-emesis, myelopoietic support, and the recent
recognition that degrees of anaemia previously assumed to be
unimportant seriously impact function and require attention. These
advances continue to improve the lives of cancer patients. As
biotechnology advances, the potential for further symptomatic
improvement for patients is indeed great. 
The recognition over the last 4 years that treatment of mild and
moderate degrees of anaemia with recombinant human erythropoi-
etin (rHuEPO) in patients with serious chronic medical conditions
such as cancer is associated with clinically significant improve-
ments in energy, activity and overall quality of life has been a
watershed event in our understanding of optimal palliative
management. I regard this as one of the most significant develop-
ments of the last decade in terms of impact on patient care. Still,
our understanding of the optimal approach to erythropoietic
management of these patients is incomplete and a better under-
standing of several key issues is required, including the relation-
ship of dose to response rate; the relationship of dose to rapidity
of response; the effect of iron supplementation on response and
the impact of treatment on the efficacy of radiotherapy and of
chemotherapy. 
This special edition of British Journal of Cancer is devoted
to darbepoetin alfa, a novel erythropoiesis stimulating protein
(NESP), and includes articles describing its preclinical develop-
ment, as well as preliminary data from clinical trials of NESP in
patients with cancer. 
Darbepoetin alfa (ARANESP™, Amgen Inc, Thousand Oaks,
CA) is the first of a new generation of erythropoiesis stimulating
proteins. It stimulates erythropoiesis by binding to the human
erythropoietin receptor, just as rHuEPO does. NESP, however, is
biochemically distinct from rHuEPO, containing additional sialic
acid, which prolongs its serum half-life and thus increases its in
vivo activity (Egrie et al, 1997). 
In the preclinical studies described by Egrie and Browne, NESP
was shown to have a serum half-life approximately 3-fold longer
than rHuEPO, resulting in increased in vivo biological activity
(Egrie and Browne, 2001). The longer half-life and increased
biological activity suggested that less frequent dosing was likely,
enhancing the potential for growth factor administration to be
synchronized with chemotherapy cycles. 
The longer half-life suggested by these preclinical studies was
confirmed when NESP was tested in human patients. In pharmaco-
kinetic studies involving patients with renal disease, NESP was
shown to have a 3-fold longer terminal half-life than rHuEPO
following intravenous administration (mean = 25.3 versus 8.5
hours,  P = 0.0008) (Macdougall et al, 1999). Subcutaneous admin-
istration extended the half-life to 48.8 hours. Furthermore, NESP
was shown to have the same excellent safety and tolerability as
rHuEPO. 
NESP license application for treatment of renal anaemia has
been filed worldwide, following extensive clinical trials demon-
strating the benefits of the drug in this patient group. The agent is
now undergoing clinical trials in patients with cancer. The prelim-
inary results of three of these studies are reported in this special
edition of British Journal of Cancer. 
In this edition, Heatherington et al confirm the extended half-
life of NESP in their pharmacokinetic study of anaemic patients
receiving concurrent chemotherapy (Heatherington et al, 2001). A
mean terminal half-life of 32.6 hours was demonstrated after
subcutaneous administration. Weekly dosing of NESP and a
dose–response relationship were examined in the dose-escalation
trial by Smith et al (Smith et al, 2001). In this trial, 61–83% of
patients with chronic anaemia of cancer who were not receiving
chemotherapy responded (increase in haemoglobin ³ 2 . 0gd l –1) to
once-weekly subcutaneous administration of 1.0–4.5 mcg kg–1
NESP. 
In a subset of a larger trial, in which 107 patients received
concurrent chemotherapy, Glaspy et al confirmed the feasibility of
reduced-frequency dosing, and showed a dose-dependent relation-
ship between NESP and multiple measures of efficacy, including
proportion of patients responding to NESP and change in haemo-
globin (Glaspy et al, 2001). NESP was well tolerated in all trials,
and there was no evidence of antibody formation. 
The final paper in this edition, by Demetri, discusses some of
the current challenges in the management of anaemic cancer
patients and considers the future role of NESP in this setting
(Demetri, 2001). Taken in aggregate, these articles suggest that
there may be dose–response and dose-rapidity of response rela-
tionships with NESP, which may enhance our ability to optimally
palliate patients. They also point to opportunities for future
investigations. 
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